Dexmedetomidine Versus Lidocaine Infusions as Adjuvants to General Anesthesia for Chronic Pain Management After Mastectomy
Dexmedetomidine Versus Lidocaine Infusions as Adjuvants to General Anesthesia for Chronic Pain Management After Mastectomy: A Randomized Controlled Trial
Cairo University
90 participants
Apr 5, 2025
INTERVENTIONAL
Conditions
Summary
This study aims to compare dexmedetomidine and lidocaine infusions as adjuvants to general anesthesia for chronic pain management after mastectomy.
Eligibility
Inclusion Criteria3
- Age from 18 to 75 years.
- American Society of Anesthesiologists (ASA) physical status II.
- Scheduled for mastectomy with axillary dissection (either modified radical mastectomy with or without latissimus dorsi flap or conservative breast surgery) due to breast cancer.
Exclusion Criteria6
- Patient refusal.
- Known allergy to any of the study drugs.
- Those with hepatic or renal insufficiency.
- Patients who are running regularly on B blockers.
- α2 adrenergic agonists and sedatives.
- Psychoactive medications.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive 1 μg/kg of intravenous dexmedetomidine over 10 min followed by an intravenous infusion of 0.5 μg/kg/h.
Patients will receive a bolus of intravenous lidocaine 1.5mg/kg over 10 min followed by a continuous infusion of lidocaine 1.5mg/kg/h.
Patients will receive intravenous isotonic saline 0.9% in the same volume and manner as the study drugs.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06910644